42 results about "Menopausal disorders" patented technology

Novel mercaptophenyl naphthyl methane compounds, their pharmaceutically acceptable salts and compositions comprised thereof are useful for the prevention or treatment of various medical indications associated with estrogen dependent diseases or syndromes related to osteoporosis, bone loss, bone formation, cardiovascular disorders, neurodegenerative disorders, menopausal disorders, physiological disorders, diabetes disorders, prostatic carcinoma, cancer of breast, cancer of uterus, cancer of the cervix and cancer of the colon, threatened or habitual abortion, obesity, ovarian development or function, post-partum lactation and depression.

Methods, formulations, and devices for providing transdermal or transmucosal delivery of active agents to subjects in need thereof. The formulations and methods treat symptoms of hormonal disorders including hypogonadism, female sexual desire disorder, female menopausal disorder, and adrenal insufficiency.

It is to provide a pharmaceutical composition which is different from an existing therapeutic agent of an adult disease, of a biochemical reaction-inhibiting type, and which action mechanism is to improve the basal metabolism, wherein the composition has no side effects, and does not generate drug resistance against adult disease; and a method for preventing/treating an adult disease by using the same. It is to provide a composition for preventing/ameliorating an adult disease such as metabolic syndrome, diabetes, hyperlipidemia, hypertension, impaired liver function, renal failure, adiposity, erectile dysfunction, menopausal disorder, shoulder discomfort, and low back pain, comprising 5-aminolevulinic acid (ALA), its derivative, or salt thereof, preferably comprising ALA, its derivative, or salt thereof, and an iron compound such as sodium ferrous citrate, iron sodium citrate and iron ammonium citrate; a food or food material for preventing/ameliorating an adult disease comprising the composition; and a method for using the composition for preparing an agent for preventing/ameliorating an adult disease.

Soymilk is provided which can prevent or alleviate menopausal disorders, and is highly safe with no risk of side effects even with long-term intake thereof. This soymilk is made from germinated soybeans, and is used for alleviating or preventing the vasomotor disorder-like symptoms and psychoneuropathic disorder-like symptoms associated with menopausal disorders. Furthermore, this soymilk is labeled with a notice specifying that the soymilk is to be used for alleviating or preventing the vasomotor disorder-like symptoms and psychoneuropathic disorder-like symptoms of menopausal disorders.

The present invention relates to the use of keratinocyte growth factor (KGF/FGF7) and pharmaceutical compositions thereof in the treatment of vaginal atrophy, dysuria, vaginal pain and/or vaginal dryness induced by a post-menopausal state, by surgical intervention, by illness and/or by chemotherapy or radiotherapy treatments.

Disclosed is a method for producing an estrogen-like active intermediate (e.g., secoisolariciresinol) by culturing a lignan (e.g., a lignan derived from Eucommia ulmoides) together with a bacterium Lactobacillus acidophilus. Also disclosed a prophylactic/ameliorating agent for menopausal disorder and a functional beverage/food for preventing/ameliorating menopausal disorder comprising a lignan cultured together with a bacterium Lactobacillus acidophilus as an active ingredient.

The present invention relates to the use of extracts from Cimicifuga racemosa, and of tectorigenin as an estrogen-type, organoselective medicament for the selective treatment and/or prophylaxis of cardiovascular diseases, atherosclerosis, osteoporosis and climacteric disorders, e.g. for preventing or alleviating hot flushes. Uterotrophic effects are practically not observed.

The present invention provides a pharmaceutical composition and health functional food composition for preventing or treating female menopausal disease including extract of Ribes fasciculatum leaves as an active ingredient, and a pharmaceutical composition and health functional food composition for preventing or treating female menopausal disease including an extract of Cornus officinalis and extract of Ribes fasciculatum leaves as active ingredients.

Provided is a composition for preventing and treating a menopausal disorder containing extracts of Dendropanax morbifera LEV. as an active ingredient. Specifically, the extracts of Dendropanax morbifera LEV. exhibit a significant ER agonist activity within a cell, and exhibit a very potent ER agonist (full agonist) activity with an EC₅₀ value of about 100 μg/ml. Thus, the extracts of Dendropanax morbifera LEV. comprising a high content of plant metabolites similar to estrogen can be useful as hormone replacement therapy capable of improving various symptoms derived from a deficiency of estrogen in menopausal women.

In one aspect, the present invention is directed to methods for treating fatigue, neurobehavioral slowing and other cognitive disorders and defects due to cancers and treatments associated with cancers, and similar conditions. In a further aspect, the present invention is directed to methods for treating disorders related to menopause, including executive function defects. The methods involve the administration of a composition comprising D-threo methylphenidate that is substantially free of L-threo methylphenidate and of erythro forms of methylphenidate.

The present invention relates to the female menopausal disorder prevention and/or the osteoporosis improvement, and the effect that is quick as to the composition of the invention is in the female menopausal disorder prevention or the improvement. Therefore the effect can be used to the hormone replacement therapy (Hormone replacement therapy: HRT) used for the prevention or the improvement of the conventional climacteric symptom. Moreover, the side effect is safe in addition the cytotoxin does not have to the therapeutic agent about the conventional female menopausal disorder the composition of the invention is used as food. Therefore the therapeutic agent can be used in comparison with the therapeutic agent about the conventional female menopausal disorder.

The present invention relates to the use of extracts from Iridaceae and from Cimicifuga racemosa, and of tectorigenin as an estrogen-type, organoselective medicament for the selective treatment and/or prophylaxis of cardiovascular diseases, in particular atherosclerose, osteoporose and climacteric disorders, e.g. for preventing or alleviating hot flushes. Uterotrophic effects are practically not observed.

The present invention relates to a composition for improvement of female menopausal (climacteric) disorders, comprising as an active ingredient a combination of a red clover extract and a hops extract, more specifically a food composition for improvement of women's menopausal disorders or a pharmaceutical composition for prevention or treatment of women's menopausal disorders, comprising as an active ingredient a combination of a red clover extract and a hops extract; and a method for preparing said composition for improvement of women's menopausal disorders.